youtube cover2.png


Srihari Raghavendra Rao, Chandrashekhar Honrao, Keri Sheehan, LeoRodrigues, Chen Dong, Elizabeth O’Day, and Dirk R. Kuypers. Non-Invasive Metabolite-Based Urine Signature Detects Over-Immunosuppression in Renal Transplant Recipients [abstract/moderated poster presentation]. Proceedings of the International Transplant Science (ITS) 2022 Meeting; 2022 May.  Full abstract to be published on ITS website May 16, 2022.

Chandrashekhar Honrao, Cristina Guarducci, Agostina Nardone, Wen Ma, Srihari Raghavendra Rao, Keri Sheehan, Chen Dong, Leo Rodrigues, Rinath Jeselsohn, Elizabeth O'Day. Isotopic Tracing Reveals Distinct Metabolic Changes with Palbociclib or Abemaciclib Treatment and Resistance in Breast Cancer Cell Lines [abstract/virtual poster presentation]. Proceedings of the 113th Annual Meeting of the American Association for Cancer Research (AACR); 2022 Apr.!/10517/presentation/17843 ​

Chen Dong, Chandrashekar Honrao, Leonardo O. Rodrigues, Josephine Wolf, Keri B. Sheehan, Matthew Surface, Roy N. Alacay, Elizabeth M. O'Day. Plasma Metabolite Signature Classifies Male LRRK2 Parkinson’s Disease Patients. Metabolites 12, 149 (2022). 

Dong C, Thomas S, Honrao C, Rodrigues LO, Tessier N, Zhang B, Sanati S, Vij KJ, Ernst BJ, Anderson KS, Opyrchal M, Ademuyiwa F, Peterson LL, Goetz MP, Northfelt D, O’Day E, Ma C. Identifying Metabolic Biomarkers of Response in Early-Stage Breast Cancer Patients. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; San Antonio (TX). SABC, 2021 Dec.  Olaris, Waltham, MA; Washington University in St. Louis, St. Louis, MO; Cedars-Sinai, Los Angeles, CA; Mayo Clinic, Phoenix, AZ; Mayo Clinic, Rochester, MN.  Program P5-13-20.

Chandrashekhar Honrao, Nathalie Teissier, Bo Zhang, Robert Powers, and Elizabeth M. O’Day. Gadolinium-based Paramagnetic Relaxation Enhancement Agent Enhances Sensitivity for NUS Multidimensional NMR-based Metabolomics. Molecules, 26(17), 5115; (2021) . 


Chandrashekhar Honrao, Srihari Raghavendra Rao, Nathalie Teissier, S. Greg Call, Elizabeth M. O’Day, Filip Janku. Plasma-based metabolic profiling in metastatic gastrointestinal stromal tumors (GIST) [abstract]. In: Proceedings of the 112th Annual Meeting of the American Association for Cancer Research; 2021 April 10-15; Virtual. Olaris, Inc., Waltham (MA), MD Anderson Cancer Center, Houston (TX): AACR, 2021. Abstract nr LB031.!/9325/presentation/4540  


Hoyt, L. & O’Day, E. M. Perspective: A potential role for NUS in metabolite-based in vitro diagnostics. Magnetic Resonance in Chemistry 59, 257–263 (2021).  


O’Day, E. M., Idos, G. E., Hill, C., Chen, J. W. & Wagner, G. Cytidine monophosphate N-acetylneuraminic acid synthetase enhances invasion of human triple-negative breast cancer cells. OTT 11, 6827–6838 (2018).  


O’Day, E.M., K. Leitzel, A. Lipton, et al. Pretreatment serum metabolome predicts PFS in first-line trastuzumab-treated metastatic breast cancer [poster]. In: Proceedings of the 2020 San Antonio Breast Cancer Symposium; San Antonio (TX). Olaris, Inc., Waltham (MA), Penn State Hershey Medical Center, Hershey (PA): SABC, 2020. P4-10-35 


Wolf, Josephine, Chen Dong, Elizabeth M. O'Day. Metabolite Biomarkers of Response (BoRs) Towards a Fingerprint for the Evolution of Metastatic Breast Cancer. Progress in Biophysics and Molecular Biology,(2021).  


Zhang, B., Powers, R. & O’Day, E. M. Evaluation of Non-Uniform Sampling 2D 1H–13C HSQC Spectra for Semi-Quantitative Metabolomics. Metabolites 10, 203 (2020).  

Zhang, B., Warner, J., Pinto, C., Juric, D. & O'Day, E. NMR-metabolite-resonance signature to predict HR+ breast cancer patient response to CDK4/6 inhibitors. Journal of Clinical Oncology 37, 3043–3043 (2019). 

Zhang, B., Powers, R. & O’Day, E.M. Evaluation of Non-Uniform Sampling 2D 1H–13C HSQC Spectra for Semi-Quantitative Metabolomics [poster]: in Experimental Nuclear Magnetic Resonance Conference; 2020. Olaris, Inc, Waltham (MA),  University of Nebraska-Lincoln, Lincoln (NE): ENC, 2020.